Wisevoter
U.S.

Zenkuda Shows Encouraging Year-One Results in Macular Trial

Phase 3 DAYBREAK data on the wet age-related macular degeneration drug were presented at the American Academy of Ophthalmology meeting.

Updated on Nov. 2, 2026 in Diabetes

Photograph of a plain clear glass vial of pale amber liquid on a white clinical tray against a soft blue wall, suggesting an eye-treatment drug.
Kodiak Sciences reported encouraging one-year phase 3 DAYBREAK results for its wet macular degeneration drug Zenkuda, which could reduce how often patients need eye injections. AI Illustration. Upload story photo >

Kodiak Sciences' Zenkuda showed encouraging one-year results in the phase 3 DAYBREAK trial for wet age-related macular degeneration. The trial also compared Zenkuda and KSI-501 against Eylea.

Why it matters

Wet age-related macular degeneration is treated with repeated eye injections, so a drug that keeps fluid from returning for longer could reduce how often patients need treatment. The results remain early and come from a single trial.

The phase 3 DAYBREAK trial reported one year of data, with 54% of Zenkuda patients going as long as 6 months without fluid reaccumulating after four loading doses. Results beyond the first year have not yet been disclosed.

The players

Kodiak Sciences

Kodiak Sciences is the biotechnology company that manufactures Zenkuda and develops the drug's clinical program.

Regeneron

Regeneron is the biopharmaceutical company that manufactures Eylea, the comparator drug in the DAYBREAK trial.

The details

Kodiak Sciences manufactures Zenkuda, whose active ingredient is tarcocimab tedromer, and the DAYBREAK trial assessed it alongside KSI-501 and Regeneron's Eylea in patients with wet AMD. The trial results were presented at the American Academy of Ophthalmology meeting.

Timeline

  1. November 2, 2026: Article published reporting the one-year DAYBREAK results.

Health Landscape

Zenkuda is being measured directly against Eylea, the long-established anti-VEGF injection for wet AMD. Whether it can match or extend Eylea's dosing intervals will determine its place in the treatment landscape.

If Zenkuda's durability holds, patients with wet AMD could need fewer injections over time. Patients should continue discussing treatment intervals and options with their retina specialists.

The takeaway

Longer dosing intervals are the key measure for wet AMD therapies, so readers should watch whether year-two data confirms the one-year durability. Treatment decisions should remain with a qualified eye care provider.

What happens next

The second year of DAYBREAK data is expected to show whether the durability seen in year one continues.

Further reading

Explore more on Diabetes and eye-related complications in the health section.